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Abstract: BACKGROUND There has been a shift in recent years to using ultrasound (US) and magnetic
resonance imaging (MRI) as first-line investigations for suspected cranial large vessel vasculitis (LVV)
and is a new recommendation by the EULAR 2018 guidelines for imaging in LVV. This cross-sectional
study compares the performance of US and MRI and contrast-enhanced magnetic resonance angiography
(MRA) for detecting vasculitis in patients with giant cell arteritis (GCA). METHODS Patients with new-
onset or already diagnosed GCA were recruited. The common temporal arteries and supra-aortic large
vessels were evaluated by US and MRI/MRA. Blinded experts read the images and applied a dichotomous
score (vasculitis: yes/no) in each vessel. RESULTS Thirty-seven patients with giant cell arteritis (GCA)
were recruited. Two patients were excluded. Of the remaining patients, nine had new-onset disease and 26
had established disease. Mean age was 71 years, and median C-reactive protein (CRP) was 7.5 mg/L. The
median time between US and MRI was 1 day. Overall, US revealed vasculitic changes more frequently
than MRI (p < 0.001). US detected vascular changes in 37% of vessels compared to 21% with MRI.
Among patients with chronic disease, US detected vascular changes in 23% of vessels compared to 7%
with MRI in (p < 0.001). The same was true for patients with new-onset disease. US detected vasculitic
changes in 22% of vessels and MRI detected disease in 6% (p = 0.0004). Compared to contrast-enhanced
MRA, US was more sensitive in detecting vasculitic changes in the large arteries, including the axillary,
carotid, and subclavian arteries. CONCLUSION US more frequently detects vasculitic changes in the
large arteries compared to contrast-enhanced MRA. When evaluating the cranial vessels, US performs
similarly to MRI. This data supports the recommendation that US be considered as a first-line evaluation
in patients suspected to have GCA.
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Abstract
Background: There has been a shift in recent years to using ultrasound (US) and magnetic resonance imaging
(MRI) as first-line investigations for suspected cranial large vessel vasculitis (LVV) and is a new recommendation by
the EULAR 2018 guidelines for imaging in LVV. This cross-sectional study compares the performance of US and MRI
and contrast-enhanced magnetic resonance angiography (MRA) for detecting vasculitis in patients with giant cell
arteritis (GCA).
Methods: Patients with new-onset or already diagnosed GCA were recruited. The common temporal arteries and
supra-aortic large vessels were evaluated by US and MRI/MRA. Blinded experts read the images and applied a
dichotomous score (vasculitis: yes/no) in each vessel.
Results: Thirty-seven patients with giant cell arteritis (GCA) were recruited. Two patients were excluded. Of the
remaining patients, nine had new-onset disease and 26 had established disease. Mean age was 71 years, and
median C-reactive protein (CRP) was 7.5 mg/L. The median time between US and MRI was 1 day. Overall, US
revealed vasculitic changes more frequently than MRI (p < 0.001). US detected vascular changes in 37% of vessels
compared to 21% with MRI. Among patients with chronic disease, US detected vascular changes in 23% of vessels
compared to 7% with MRI in (p < 0.001). The same was true for patients with new-onset disease. US detected
vasculitic changes in 22% of vessels and MRI detected disease in 6% (p = 0.0004). Compared to contrast-enhanced
MRA, US was more sensitive in detecting vasculitic changes in the large arteries, including the axillary, carotid, and
subclavian arteries.
Conclusion: US more frequently detects vasculitic changes in the large arteries compared to contrast-enhanced
MRA. When evaluating the cranial vessels, US performs similarly to MRI. This data supports the recommendation
that US be considered as a first-line evaluation in patients suspected to have GCA.
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Background
Giant cell arteritis (GCA) is a type of large vessel vascu-
litis (LVV) that affects the walls of medium- and large-
sized arteries. Granulomatous inflammation in GCA
causes thickening of the arterial wall with subsequent
stenosis, and in some cases, complete occlusion resulting
in ischemic damage of tissue distal to the affected vessel.
Some patients may develop aneurysms, especially in
long-standing disease [1].
GCA affects individuals older than 50 years of age [2,
3]. The annual incidence of GCA in Norway is one of
the highest worldwide, affecting 29–32 patients per 100,
000 population aged 50 years or more [4, 5].
GCA may affect the cranial arteries (e.g., temporal ar-
tery) only, extracranial large arteries only, or both the
cranial and extracranial arteries. LVV has been observed
in up to 67% of patients with temporal artery biopsies
showing GCA and up to 83% in GCA patients evaluated
by positron emission tomography (PET) scan [6, 7]. The
most common large vessels affected by GCA are the
branches of the aortic arch, including the carotid, sub-
clavian, and axillary arteries. The vertebral arteries and
the aorta may also be involved. Stenosis, occlusions, and
aneurysms are often seen in the large vessels with subse-
quent ischemia in vital organs including the heart, lungs,
kidneys, and brain [8].
As the 1990 American College of Rheumatology
(ACR) classification criteria for GCA and temporal ar-
tery biopsy primarily identifies patients with cranial in-
volvement in GCA, vascular imaging plays an important
role in the diagnosis of GCA and other forms of LVV
such as TAK [9]. Ultrasound (US), magnetic resonance
imaging (MRI) including magnetic resonance angiog-
raphy (MRA) with contrast enhancement, computed
tomography angiography (CTA), and FDG-PET/com-
puted tomography (FDG-PET/CT) are used to evaluate
vessel involvement in LVV [10, 11].
US is an inexpensive method of examining medium
and large vessels and provides high-resolution images of
the superficial blood vessels (temporal, carotid, vertebral,
axillary, and subclavian arteries). Although the descend-
ing thoracic aorta is unable to be evaluated by transtho-
racic US, US can evaluate the aortic arch and the
ascending aorta [12, 13]. With US, inflammation of the
arterial wall is observed in B mode as homogenous en-
largement of the inner two layers, the intima and media,
together called the intima-media complex (IMC). When
seen in a transverse view, intima-media thickening ap-
pears as a hypoechoic rim around the vessel, called a
halo. Stenosis can be confirmed with visualization of ar-
terial lumen narrowing with color Doppler or by in-
creased flow velocity with duplex Doppler. US is readily
available without long wait times or insurance appeals,
and individuals can be examined in a timely manner.
Because of these advantages, the European League
Against Rheumatism (EULAR) recommends US as the
preferred imaging modality in patients with suspected
GCA [12].
MRI can confirm the diagnosis of vasculitis in superfi-
cial and deep vessels. With MRI, vascular inflammation
is observed as increased vessel wall thickness and edema
with increased mural enhancement on high-resolution
post-contrast T1-weighted images. MRA with contrast
enhancement can reveal segmental stenosis of the af-
fected arteries. MRI may not be able to be performed in
patients with relative contraindications to this imaging
modality including renal failure, pregnancy, indwelling
pacemaker or defibrillator, history of working with
metal, or claustrophobia.
The aim of this study is to present a head-to-head
comparison of the diagnostic accuracy of US and MRI of
the temporal arteries and contrast-enhanced MRA of
the supra-aortic large vessels in patients with GCA.
Methods
Patient recruitment
In this cross-sectional study, patients diagnosed with
GCA were recruited between 1 January 2014 and 1 Janu-
ary 2015, referred from the outpatient clinic of the De-
partment of Rheumatology, Hospital of Southern
Norway Trust.
Patients were included if they met the ACR 1990 clas-
sification criteria for GCA [9]. The diagnosis was based
on clinical assessment, in conjunction with imaging of
temporal arteries and large supra-aortic vessels (US,
MRA, CTA, or FDG-PET/CT) and/or biopsy of the tem-
poral artery (Supplementary Table S1). Patients were re-
evaluated at 6 and 12months after study entry, and diag-
nosis was confirmed by clinical re-evaluation after 1 year.
Patients with new-onset and long-standing GCA were
recruited. New-onset disease was defined as disease on-
set within 2 months of study recruitment. All patients
with new-onset disease received prednisolone 60 mg at
the time of US examination, except for one patient, who
received 20mg. Long-standing disease was defined as
disease diagnosed at least 6 months prior to study entry.
Participants with chronic disease were classified as hav-
ing either active or inactive disease according to clinical
evaluation. Active disease was defined as the presence of
typical signs or symptoms of GCA (including polymyal-
gia symptoms, headache, claudication in the arms or
jaw, or fatigue not attributable to other causes) and an
increase in inflammatory markers [14]. Remission was
defined as the absence of all clinical signs and symptoms
attributable to GCA and normalization of inflammatory
markers [14]. Patients with moderate to severe kidney
failure or known allergic reactions to contrast agents
were excluded. All patients underwent US evaluation of
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the temporal arteries and supra-aortic large vessels. A
clinical assessment and C-reactive protein (CRP) were
done on the same day of US evaluation. MRI/MRA of
the same vessels was performed within 1 week after US
evaluation.
Ultrasound (US) examination
All patients underwent US evaluation with a Siemens
Acuson S-2000 with two multi-frequency linear trans-
ducers (6–18MHz and 4–10MHz) for the temporal ar-
tery and superficial supra-aortic vessels and a phased-
array transducer (2–5MHz) for the examination of the
ascending aorta and aortic arch. Doppler settings were
optimized according to the published guidelines for the
use of Doppler US in LVV [15]. Cine clips of 3 s were re-
corded in both B mode and color Doppler for US. Meas-
urement of the intima-media complex (IMC) thickness
of the arteries was performed with static images. The
highest IMC thickness measurement was recorded in
longitudinal and transverse views. The common tem-
poral, carotid, subclavian, vertebral, and axillary arteries;
aortic arch; and ascending thoracic aorta were evaluated.
Vasculitis by US was defined as a homogeneous hypoe-
choic thickening of the vessel with increased IMC thick-
ness (Fig. 1a, b). Cut-off values for abnormal IMC
thickness were 2.5 mm for the aorta, 1.5 mm for the ca-
rotid and subclavian arteries, and 1.0 mm for the verte-
bral and axillary arteries. Data in this study was collected
before cut-off values for normal IMC thickness had been
defined. Abnormal IMC thickness was later defined as
0.42, 0.34, 0.29, 0.37, and 1.0 mm for the common tem-
poral, frontal temporal, parietal temporal, facial, and ax-
illary arteries, respectively [16]. For the temporal artery,
the presence of a halo (a circumferential, hypoechoic
thickening of IMC in transverse and longitudinal views)
was considered as a marker of vasculitis.
Magnetic resonance imaging (MRI)
1.5-Tesla (1.5 T) MRI was performed in all patients in
two sequences. High-resolution T1-weighted spin echo
sequences with fat saturation were obtained to assess the
cranial arteries, and contrast-enhanced MRA was used
to assess the thoracic aorta and supra-aortic arteries
(Supplementary Data S1) [10, 17]. Vasculitic changes on
MRI are seen as mural thickening. Previously established
criteria were used to define mural thickening of the cra-
nial arteries [18, 19]. Mural thickening was evaluated
using a 4-point ranking scale: 1 is no mural thickening
and no mural enhancement, 2 is no mural thickening
with only slight contrast enhancement, 3 is mural thick-
ening and prominent mural enhancement, and 4 is
strong mural thickening and strong mural enhancement.
In MRA, information about the lumen of the artery and
inflammation was assessed indirectly by stenosis (Fig. 1c).
Additional transverse post-gadolinium sequences in the
large vessels were not performed.
Anonymized US clips and MRI images were recorded
and stored in a database at the Hospital of Southern
Norway.
Locally, one ultrasonographer (APD) with 5 years of
experience and one radiologist (FL) with 1 year of ex-
perience acquired and interpreted the US and MRI im-
ages, respectively. The two local evaluators were not
blinded to clinical and imaging data. The anonymized
images were then reviewed by two external experts, one
in vascular ultrasound (WAS) and one in MRI (JG). Both
Fig. 1 Ultrasound images revealing homogeneous hypoechoic increased intima-media thickness of the axillary (a) and subclavian (b) arteries
(white arrows). Magnetic resonance angiography (MRA) (c) of the same patient revealing large vessel involvement, with stenosis of both
subclavian arteries (white arrows) and axillary arteries (arrowheads)
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external readers were blinded to previous imaging, as
well as clinical and laboratory data, and unaware of the
distribution and size of the vasculitic lesions. The exter-
nal readers applied a dichotomous score (vasculitis: yes/
no) to each evaluated vessel. In order to control for bias,
interpretation by the two external experts was used to
confirm the diagnosis of vasculitis. The identification of
vasculitis in any vessel represented an independent
result.
Costs of imaging
The cost of the ultrasound examination was approxi-
mately 1000 Norwegian crowns (NOK) ($100 USD),
while an MRI and MRA with contrast enhancement of
cranial and large vessels cost 4000 NOK ($430 USD).
Statistical analysis
Due to the lack of previous studies comparing US to
MRA with contrast enhancement, the study sample was
not calculated, and consequently, the study was explora-
tory. Interobserver agreement between the two sonogra-
phers (WAS and ADP) and the two radiologists (JG and
FL) was assessed using Cohen’s kappa statistics (poor
agreement: kappa < 0.40; moderate agreement: kappa
0.40–0.59; good agreement: kappa 0.60–0.79; excellent
agreement: kappa ≥ 0.80). A significant difference be-
tween US and MRI was calculated using the McNemar
test or the exact McNemar test when data were sparse.
All analyses were performed using SAS 9.4. A Poisson
regression model was performed to determine the pre-
dictors on the number of vessels with vasculitic changes
on imaging. The predictors of interest were age, sex, dis-
ease status, and CRP.
Results
Thirty-seven patients were recruited during the inclu-
sion period. Two patients were excluded: in one patient,
MRA was contraindicated due to the presence of a pace-
maker, and in the second, severe back pain did not allow
for MRA examination. Of the remaining 35 patients, 13
(37%) were male and 22 (63%) were female. The median
age was 71 years (IQR 63–78 years). Nine patients had
new-onset disease and 26 had established disease (me-
dian disease duration 2.5 years, (0–4 years)). Among the
patients with new-onset disease, seven had active disease
and two were in remission. Of the patients with estab-
lished disease, 19 patients were in clinical remission and
seven patients had active disease. The median time be-
tween US and MRI examinations was 1 day (IQR 0–2
days). The median CRP was 7.5 mg/L (IQR 3–16mg/L).
Patient characteristics are shown in Table 1.
The temporal arteries and the supra-aortic vessels in
which US, MRI, or both modalities revealed vasculitic
changes are presented in Supplemental Table S2 with p
values presented in Supplemental Table S3. Overall, US
detected vasculitic changes more frequently than MRI in
Table 1 Patient characteristics
All New-onset GCA Established GCA
Gender
Female 22 5 17
Male 13 4 9
Mean age, years 71 72 65




Visual manifestations 5 0 5
Jaw claudication 1 1 0
Arm claudication 3 1 2
Patients having temporal artery biopsy (TAB) 23 2 21
TAB positive 15 1 14
CRP (range) g/L 7.5 (1–200) 24 (4–200) 4 (1–57)
Corticosteroid dose (range) mg/day 5 (0–60) 60 (20–60) 5 (0–25)
Steroid sparing medications
Methotrexate 4 0 4
Leflunomide 2 0 2
Etanercept 1 0 1
GCA giant cell arteritis, TAB temporal artery biopsy, CRP C-reactive protein
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the nine patients with new-onset disease, with changes
reported in 77 vessels with US compared to 55 vessels
with MRI (p = 0.0004). However, there was no statistical
disagreement between US and MRI for any individual
vessel. US detected disease more frequently than MRI in
patients with chronic disease (p < 0.001). When examin-
ing individual vessels, US was more sensitive than MRA
in detecting changes in the axillary (Lt p ≤ 0.001, Rt p <
0.0003), carotid (Lt p < 0.02, Rt p < 0.001), and subclavian
arteries (Lt p < 0.0005, Rt p < 0.02) (Fig. 2), whereas MRI
was more sensitive in detecting vasculitic changes in the
right temporal frontal artery (Supplemental Table S2
and S3). For the remainder of the vessels, there was no
statistical difference between the imaging modalities in
the ability of each imaging modality to detect vasculitic
changes. Of note, there was an excellent interobserver
agreement between the ultrasonographers (kappa 0.84;
95% CI 0.79–0.89), whereas there was moderate agree-
ment between the radiologists (kappa 0.44; 95% CI 0.33–
0.54) (Table 2).
The correlation between vasculitic changes on imaging
and active disease was evaluated. The lack of vasculitic
changes on MRI/MRA was significantly associated with
disease remission, whereas with US, vasculitic changes
were seen in both active and inactive disease. There was
45.7% concordance (p = 0.23) between US and disease
activity, whereas there was 68.6% concordance (p = 0.01)
for MRI (Fig. 3). Among the two imaging modalities, the
average CRP was similar (Fig. 4).
Poisson regression models were used to identify pre-
dictors of the number of vessels with vasculitic changes
on imaging. Active disease significantly predicted a
higher number of vessels affected by MRI (p = 0.004),
whereas CRP predicted a higher number of vasculitic
changes detected by US (p = 0.02).
Discussion
Historically, the diagnosis of GCA has been made on
clinical grounds and confirmed with temporal artery bi-
opsy. There has been a shift in recent years to using
US and MRI as first-line investigations for suspected
cranial LVV and is a new recommendation by the
EULAR 2018 guidelines for imaging in LVV [12, 20,
21]. A recent meta-analysis reported US of the tem-
poral arteries had a pooled sensitivity of 77% and spe-
cificity of 96%. High-resolution 3-T MRI had a
pooled sensitivity of 77% and specificity of 88% [21].
The EULAR recommendations for imaging in LVV
state a need for prospective studies directly compar-
ing US and MRI.
The EULAR recommendations for imaging in LVV
recommend the use of high-resolution 3-T MRI;
however, studies comparing high-resolution 3-T MRI
to US may not be applicable in practice as most
centers only have access to 1-T or 1.5-T MRI ma-
chines [12, 21].
Fig. 2 Ultrasound images (a) revealing increased intima-media thickness of the right axillary artery, measured at 1.8 mm on the upper vessel wall,
compared to magnetic resonance angiography (b) in the same patient, which did not reveal evidence of vasculitis in the same vessel
Table 2 Cohen’s kappa for interobserver agreement between
sonographers and radiologists
Vessel Sonographers Radiologists
Lt axillary 0.94 (95% CI 0.83–1.00) 0.48 (95% CI − 0.12–1.00)
Lt carotid 0.68 (95% CI 0.42–0.94) 0.00 (95% CI 0.00–0.00)
Lt subclavian 1.00 (95% CI 1.00–1.00) 0.43 (95% CI − 0.03–0.90)
Lt temporal 0.94 (95% CI 0.83–1.00) 0.25 (95% CI − 0.03–0.53)
Lt frontal 0.65 (95% CI 0.40–0.90) 0.35 (95% CI 0.01–0.68)
Lt parietal 0.76 (95% CI 0.55–0.98) 0.31 (95% CI −0.03–0.65)
Lt vertebral 0.72 (95% CI 0.36–1.00) Not calculated
Rt axillary 1.00 (95% CI 1.00–1.00) − 0.05 (95% CI − 0.14–0.04)
Rt carotid 0.43 (95% CI 0.13–0.73) 0.65 (95% CI 0.02–1.00)
Rt subclavian 0.82 (95% CI 0.63–1.00) 0.20 (95% CI − 0.26–0.67)
Rt temporal 1.00 (95% CI 1.00–1.00) 0.44 (95% CI 0.14–0.75)
Rt frontal 0.77 (95% CI 0.52–1.00) 0.49 (95% CI 0.19–0.78)
Rt parietal 0.82 (95% CI 0.63–1.00) 0.29 (95% CI 0.02–0.57)
Rt vertebral 1.00 (95% CI 1.00–1.00) Not calculated
Thoracic aorta 0.72 (95% CI 0.35–1.00) 0.00 (95% CI 0.00–0.00)
All vessels 0.84 (95% CI 0.79–0.89) 0.44 (95% CI 0.33–0.54)
NB. Statistics could not be calculated in the left and right vertebral arteries
among the radiologists because data was too sparse
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Our study showed that US was able to detect vasculitic
changes similarly to 1.5-T MRI. There was no statistical
difference between US and MRI in any of the cranial
vessels, except the right frontal artery where MRI de-
tected vasculitis in 17 (52%) patients and US detected
changes in 7 (21%) (p < 0.002). Previous studies suggest
1.5-T MRI is less sensitive than US for detecting tem-
poral artery vasculitis; however, our study did not sup-
port this finding [22].
This is the first study to compare US to MRA for the
examination of extracranial large vessels in GCA. US de-
tected vasculitic changes in the supra-aortic arteries
more frequently than MRA. For example, US detected
disease in the left axillary artery in 19 patients (58%) and
in the right axillary artery in 25 patients (76%) compared
to 3 (9%) and 5 (15%) with MRA, respectively (p < 0.001
and < 0.0003, respectively). This may be due to the fact
that US provides higher resolution than contrast-
enhanced MRA. MRA provides information about the
lumen of the artery, and inflammation is assessed indir-
ectly by stenosis. Minor vasculitic changes within the
walls of the vessel may not have been detected without
additional transverse post-gadolinium sequences in the
large vessels. The abdominal aorta was omitted from
analysis because additional MRA images would be re-
quired to evaluate the vessel in full. This may have con-
tributed to the lower sensitivity of MRA compared to
US in the large vessels. Because the axillary artery is one
of the most common vessels involved in GCA, these
findings suggest that US will perform better than MRA
for the detection of GCA in the large arteries.
In patients with new-onset disease, glucocorticoids
were initiated at the time of US examination, but for
those with chronic disease, data regarding the initiation
Fig. 3 Vasculitic changes on imaging and disease activity. Normal magnetic resonance imaging (MRI) is significantly associated with disease
remission (p = 0.01), whereas vasculitic changes may remain visible on ultrasound (US) regardless of disease activity (p = 0.23)
Fig. 4 Distribution of C-reactive protein (CRP) by group. CRP was similar between the two imaging modalities. CRP was significantly correlated
with vasculitic changes on MRI (p = 0.04), but not with US (p = 0.50). X represents mean CRP; middle bar represents the median CRP, and whiskers
represent the upper and lower quartiles
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of glucocorticoids was not obtained. One study found
that the sensitivity of US and MRI to detect vasculitis in
the cranial vessels decreases similarly with glucocorticoid
use [23]. There is marked loss of sensitivity of US to
50% and MRI to 56% after more than 4 days of gluco-
corticoid treatment. However, there are no studies com-
paring the effects of glucocorticoid use on US and MRA
of the large vessels. The use of glucocorticoids may
affect the sensitivity of MRA more so than US and may
account for the higher detection rate with US. Further-
more, this may explain the higher concordance seen be-
tween MRA and disease activity. Resolution of contrast
enhancement on MRA is reduced after 4–5 days of
glucocorticoid therapy, whereas large vessel changes on
US may remain detectable for months in the majority of
patients, even after normalization of systemic inflamma-
tory markers [24, 25]. The probability for MRA to detect
vessel wall enhancement after more than 5 days of
glucocorticoid therapy is reduced by 89.3% [26]. The
lasting changes seen with US may make US the prefera-
ble imaging modality for disease detection.
US is able to detect vasculitic changes in the cranial and
extracranial arteries, seen as a halo sign, a positive com-
pression sign, stenosis, or occlusion. When extracranial
arteries are examined, there is a marginal improvement in
sensitivity by 2%, as seen in a study that compared exam-
ination of the temporal and axillary arteries compared to
temporal artery alone [27]. However, in clinical practice,
most protocols include the examination of additional cra-
nial and large vessels. In our study, US detected vasculitic
changes more frequently in the extracranial arteries than
MRA, but the study was not designed to examine whether
evaluating additional arteries increased the sensitivity of
US for the diagnosis of GCA. Further research is needed
to clarify whether the evaluation of additional vessels in-
creases diagnostic accuracy.
Rapid diagnosis of GCA using US has resulted in a sig-
nificantly reduced number of GCA patients with vision
loss [28]. With US, the radiation exposure of CTA and
FDG-PET/CT is avoided. Furthermore, patients who
have contraindications to the use of MRI and contrast
agents can be imaged with US. US is less time consum-
ing and cheaper compared to MRI. Taking into account
that US detects more abnormalities in the large vessels
than MRA, and the reduced costs to perform the exam-
ination compared to MRI, one could conclude that US is
more cost-effective than MRI. However, our study was
not designed to examine the cost-effectiveness of the
two imaging modalities and this conclusion should be
interpreted with caution.
The excellent interobserver agreement among the
sonographers and the moderate agreement among the
radiologists could be attributed to the different experi-
ence among the readers. While both ultrasonographers
performed vascular ultrasound for over 5 years, the local
radiologist (FL) had limited experience on the interpret-
ation of MRI and MRA images. This finding underscores
the importance of adequate training programs for all
personal performing or interpreting imaging modalities
which are visualizing vascular structures.
The limitations of this study include the small sample
size (n = 35) and cross-sectional study design, whereby
treating physicians were not blinded to the patient’s clin-
ical presentation when interpreting imaging results. This
was controlled for by having external blinded reviewers
interpret the images. Of note, there was no control
group presented to radiologists for comparison.
Data in this study was collected before cut-off values
for normal IMC thickness had been defined. Abnormal
IMC thickness was later defined as 0.42, 0.34, 0.29, 0.37,
and 1.0 mm for the common temporal, frontal temporal,
parietal temporal, facial, and axillary arteries, respect-
ively. In addition, compression testing on US was not
performed in this study. Both could have had an impact
on the accuracy of US.
Conclusion
The results of this study provide support for the
utilization of US in the detection of GCA. Although the
study was not powered to compare diagnostic accuracy
between US and MRI/MRA, US detected vascular
changes more frequently than MRA when examining the
axillary, carotid, and subclavian arteries. US has previ-
ously been shown to have comparable sensitivity and
specificity to MRI but is more readily available and less
expensive, making it a preferable imaging modality.
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